Dergiler / Medeniyet Medical Journal / 2019 / Cilt: 34 - Sayı: 4

Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis

Sayfa
354–359
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

At this point, FIB-4 score stands out with high sensitivity and specificity especially in the prediction of severe fibrosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Nowadays, the incidence of non-alcoholic fatty liver and steatohepatitis (NASH) is increasing and early diagnosis is of great importance.
📊
Temel Bulgular & Veri:In this study, we investigated the place of Fibrosis-4 (FIB-4), Aspartate Aminotransferase to Platelet Ratio (APRI) and AST/ALT Ratio in predicting liver fibrosis and its most optimal cut-off value in NASH patients undergoing liver biopsy.Method: Patients with NASH who underwent liver biopsy were included in the study.
💡
Sonuç & Katkı:At this point, FIB-4 score stands out with high sensitivity and specificity especially in the prediction of severe fibrosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Nowadays, the incidence of non-alcoholic fatty liver and steatohepatitis (NASH) is increasing and early diagnosis is of great importance. In this study, we investigated the place of Fibrosis-4 (FIB-4), Aspartate Aminotransferase to Platelet Ratio (APRI) and AST/ALT Ratio in predicting liver fibrosis and its most optimal cut-off value in NASH patients undergoing liver biopsy.Method: Patients with NASH who underwent liver biopsy were included in the study. Biopsy results of all patients were evaluated histopathologically and grade of fibrosis was graded. In addition, FIB-4, APRI and AST/ALT scores were calculated and compared with biopsy findings in these patients.Results: A total of 88 patients were included in the study. Of these patients 51 (58%) were female and the mean age of the study population was 52.7±9.5. According to biopsy results, NASH was detected in 79 (89.8%) and NAFLD in 9 (10.2%) patients. The cut-off values of 2.16 for FIB-4 score showed the highest predictive value in predicting advanced fibrosis. AST/ALT ratio had not any diagnostic value.Conclusion: FIB-4 and APRI scores play an important role in the noninvasive prediction of fibro-sis in NASH patients, but the AST/ALT ratio is not sufficient. On the other hand, although the guidelines recommend using these scoring systems as a screening tool, there is no clarity as to the appropriate ideal cut-off values. At this point, FIB-4 score stands out with high sensitivity and specificity especially in the prediction of severe fibrosis.

🔖

Bu Makaleye Atıf Yap

KESKİN, E. B., ÇOBAN, G. (2019). Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. Medeniyet Medical Journal, Cilt: 34 - Sayı: 4, 354–359. https://ajindex.com/articles/283234

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [CrossRef] 2. Younossi ZM, Stepanova M, Rafiq N, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonal-coholic fatty liver disease. Hepatol Commun. 2017;1:421-428. [CrossRef] 3. Chalasani N, Younossi Z, Lavine JE, et al. The diagno-sis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [CrossRef] 4. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome incre-ase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e0214. [CrossRef] 5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [CrossRef] 6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-21. [CrossRef] 7. Tuten MF, Ozdamarlar U, Yilmabasar MG, Kutlu Y, Hayir-lioglu DA, Kuru LI. Correlation of histopathological and MRI findings in non-alcoholic fatty. Goztepe Tip Dergisi. 2014;29:82-87. [CrossRef] 8. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enz-ymes. Hepatology. 2006;44:865-73. [CrossRef] 9. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477-81. [CrossRef] 10. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastro-enterology. 2005;128:1898-906. [CrossRef] 11. Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61:1356-64. [CrossRef] 12. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455-60. [CrossRef] 13. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); Eu